Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma

Blood Neoplasia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles